reports
- Jonathan Moreland
RF REGIONS FINANCIAL CORPORATION
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EGBN EAGLE BANCORP INC.
DLTR DOLLAR TREE INC.
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
SWKS SKYWORKS SOLUTIONS INC.
HTLD HEARTLAND EXPRESS INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
CET CENTRAL SECURITIES CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
WDFC WD-40 COMPANY
FEIM FREQUENCY ELECTRONICS INC.
AINC ASHFORD
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
ATOM ATOMERA
LOVE LOVESAC
FVCB FVCBANKCORP
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
RYES CAPRICOR THERAPEUTICS
HQL PATRIOT MINEFINDERS INC.
SOWG TEKLA LIFE SCIENCES INVESTORS
CPZ SOW GOOD INC.
AUID CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
JBHT IPSIDY INC.
TBBK J.B. HUNT TRANSPORT SERVICES
MPA INC.
FTHY THE BANCORP
AIKI INC.
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BUKS FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
ACRV AIKIDO PHARMA INC.
ZURA BIOHAVEN LTD
ABEO BUTLER NATIONAL CORP
STCN ACRIVON THERAPEUTICS INC
KRRO ZURA BIO LTD
LSXMA ABEONA THERAPEUTICS INC.
EP STEEL CONNECT INC
INTZ KORRO BIO INC
LGVN LIBERTY SIRIUSXM GROUP
OCX EMPIRE PETROLEUM CORP
EYPT INTRUSION INC
IZEA LONGEVERON INC
CFFI ONCOCYTE CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
C&F FINANCIAL CORPORATION
- Jonathan Moreland
FFIN FIRST FINANCIAL BANKSHARES INC
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
PCB PACIFIC CITY FINANCIAL CORP
RYES PATRIOT MINEFINDERS INC.
HQL TEKLA LIFE SCIENCES INVESTORS
BHRB BURKE & HERBERT BANK & TR/VA
NPCT NUVEEN CORE PLUS IMPACT FD
GNLX GENELUX CORP
LSXMK LIBERTY SIRIUSXM GROUP
NBBK NB BANCORP INC.
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
- Jonathan Moreland
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately. Mr. Hooks joins Applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding various leadership roles. M...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study i...
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs...
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in...
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024 NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present full results from the Phase 3 ARISE-HF study evaluating AT-001 (caficrestat) in Diabetic Cardiomyopathy (DbCM) in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Sci...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Result...
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023. Company Highlights Durable si...
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date f...
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months...
Molecular Templates Announces $9.5 Million Private Placement Offering ...
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated secu...
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financia...
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 Announced positive results from 12-month interim analysis of govorestat in ongoing INSPIRE Phase 3 trial in SORD Deficiency; Company plans to request pre-NDA meeting with neurology division of FDA Strengthened balance sheet with $100 million Private Placement, expected to extend cash runway into 2026 NEW...
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase I study AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, toda...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
SHBI SHORE BANCSHARES INC.
PNNT PENNANTPARK INVESTMENT
NGL NGL ENERGY PARTNERS LP
LOB LIVE OAK BANCSHARES
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
EMKR EMCORE CORP.
CTBI COMMUNITY TRUST BANCORP INC.
CRMT AMERICA'S CAR-MART INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
ATRC ATRICURE INC.
ASYS AMTECH SYSTEMS INC.
HWBK HAWTHORN BANCSHARES
RIGN TRANSOCEAN LTD.
PLBC PLUMAS BANCORP
HCC WARRIOR MET COAL INC.
IOVA IOVANCE BIOTHERAPEUTICS INC
NANX NANOPHASE TECHNOLOGIES CORP.
CSPI CSP INC.
FSK FS KKR CAPITAL CORP
NOVA SUNNOVA ENERGY INTERNATIONAL
MRBK MERIDIAN
PLCE THE CHILDREN'S PLACE RETAIL STORES
LRMR INC.
THRY LARIMAR THERAPEUTICS INC
ABCL THRYV HOLDINGS
LUMN ABCELLERA BIOLOGICS
SANA LUMEN TECHNOLOGIES INC.
ONDS SANA BIOTECHNOLOGY
WES ONDAS HOLDINGS
TRST WESTERN MIDSTREAM PARTNERS LP
STGW TRUSTCO BANK CORP NY
MODD STAGWELL INC
VFC MODULAR MEDICAL INC
GATO VF CORPORATION
CYT SUNSHINE SILVER MINING AND REFINING CORP
ADXS CYTEIR THERAPEUTICS INC
BNL AYALA PHARMACEUTICALS INC
BROADSTONE NET LEASE INC
Applied Therapeutics Announces $100 Million Private Placement
Applied Therapeutics Announces $100 Million Private Placement Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2026 NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has entered into...
Applied Therapeutics Announces FDA Acceptance and Priority Review of N...
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia PDUFA target action date of August 28, 2024 MAA validated and accepted for review by EMA in December 2023 NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the fi...
- Jonathan Moreland
PNNT PENNANTPARK INVESTMENT
NYCB NEW YORK COMMUNITY BANCORP INC.
NGL NGL ENERGY PARTNERS LP
NBTB NBT BANCORP INC.
MKL MARKEL CORPORATION
LOB LIVE OAK BANCSHARES
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
EMKR EMCORE CORP.
CVBF CVB FINANCIAL CORP.
CTBI COMMUNITY TRUST BANCORP INC.
CRMT AMERICA'S CAR-MART INC.
CPRX CATALYST PHARMACEUTICALS
ASYS AMTECH SYSTEMS INC.
ADVM ADVERUM BIOTECHNOLOGIES
VIRT VIRTU FINANCIAL INC. CLASS A
HWBK HAWTHORN BANCSHARES
THR THERMON GROUP HOLDINGS
HI HILLENBRAND INC.
PLBC PLUMAS BANCORP
CIZN CITIZENS HOLDING CO.
CLSD CLEARSIDE BIOMEDICAL INC
KREF KKR REAL ESTATE FINANCE TRUST
NEE NEXTERA ENERGY
IOVA INC.
NANX IOVANCE BIOTHERAPEUTICS INC
CSPI NANOPHASE TECHNOLOGIES CORP.
PLCE CSP INC.
LRMR THE CHILDREN'S PLACE RETAIL STORES
LUMN INC.
SANA LARIMAR THERAPEUTICS INC
TRST LUMEN TECHNOLOGIES INC.
MODD SANA BIOTECHNOLOGY
BPRN TRUSTCO BANK CORP NY
VFC MODULAR MEDICAL INC
CYT BANK OF PRINCETON
PCSA VF CORPORATION
ADXS CYTEIR THERAPEUTICS INC
PROCESSA PHARMACEUTICALS INC
AYALA PHARMACEUTICALS INC
- Jonathan Moreland
Applied Therapeutics Announces Positive Results from 12-month Interim ...
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05) Sustained, statistically significant reduction in sorbitol in govorestat-treated patients vs. placebo (p
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare L...
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference. Oppenheimer 34rd Annual Healthcare Conference, February 13 – 14 Format: Virtual PresentationDate: Wednesday, February 14, 2024Time: ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PBF PBF ENERGY INC. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CVI CVR ENERGY INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
HTBI HOMETRUST BANCSHARES INC
MOG.A MOOG INC. CLASS A
AXP AMERICAN EXPRESS COMPANY
COF CAPITAL ONE FINANCIAL CORPORATION
ISTR INVESTAR HOLD
PVH PVH CORP.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
KALV KALVISTA PHARMACEUTICALS
GLOB GAZIT-GLOBE LTD.
AOUT AMERICAN OUTDOOR BRANDS
NKTX INC.
WMG NKARTA
ABNB WARNER MUSIC GROUP CORP. CLASS A
EYPT AIRBNB INC. CLASS A
PSFE EYEPOINT PHARMACEUTICALS
VERA PAYSAFE LTD.
EWTX VERA THERAPEUTICS INC
LBTYA EDGEWISE THERAPEUTICS INC
AEON LIBERTY GLOBAL PLC
AEON BIOPHARMA INC
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase...
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months AT-001 treatment resulted in a statistically significant difference in cardiac functional capacity in a prespecified subgroup of patients not receiving concomitant treatment with an SGLT2 or GLP-1 (p=0.040) and prevented clinically significant worsening (odds ratio 0.56; p=0.035) AT-001 demonstrated a favorable safety and tolerability ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.